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Free radicalsosis (ALS) is an adult-onset neurodegenerative disease, characterized by
progressive dysfunction and death of motor neurons. Although evidence for oxidative stress in ALS
pathogenesis is well described, antioxidants have generally shown poor efﬁcacy in animal models and
human clinical trials. We have developed an in vitro screening cascade to identify antioxidant molecules
capable of rescuing NSC34 motor neuron cells expressing an ALS-associated mutation of superoxide
dismutase 1. We have tested known antioxidants and screened a library of 2000 small molecules. The library
screen identiﬁed 164 antioxidant molecules, which were reﬁned to the 9 most promising molecules in
subsequent experiments. Analysis of the in silico properties of hit compounds and a review of published
literature on their in vivo effectiveness have enabled us to systematically identify molecules with antioxidant
activity combined with chemical properties necessary to penetrate the central nervous system. The top-
performing molecules identiﬁed include caffeic acid phenethyl ester, esculetin, and resveratrol. These
compounds were tested for their ability to rescue primary motor neuron cultures after trophic factor
withdrawal, and the mechanisms of action of their antioxidant effects were investigated. Subsequent in vivo
studies can be targeted using molecules with the greatest probability of success.
© 2009 Elsevier Inc. Open access under CC BY license.Amyotrophic lateral sclerosis (ALS)1 is an adult-onset neurodegen-
erative disease characterized by progressive dysfunction and death of
motor neurons (MNs) in the motor cortex, brain stem, and spinal cord.
The cause of disease is unknown in the majority of cases, classiﬁed
as sporadic ALS, but approximately 10% of cases have a genetic cause.
ALS-causing mutations have been identiﬁed in several genes, of which
the best described is mutation of Cu,Zn superoxide dismutase (SOD1),
responsible for approximately 20% of familial cases [1]. Sporadic and
familial ALS are clinically indistinguishable and there is good evidence
to suggest that they share a common pathogenic mechanism that
includes oxidative stress, excitotoxicity, mitochondrial dysfunction,
protein aggregation, axonal transport defects, and inﬂammatory
cascades [2]. Precisely how mutations in SOD1 lead to MN death is
still unclear, although there are likely to be multiple mechanisms′-azobis(2-methylpropionami-
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 license.because over 100 disease-causingmutations have been identiﬁed in the
154-amino-acid protein. Some SOD1 mutants develop a free radical-
generating ability (reviewed in [3]), andmutant SOD1has recently been
shown to cause sustained activation of NADPH oxidase, leading to
increased superoxide production [4], and to induce endoplasmic
reticulum stress, leading to apoptosis [5,6]. Increasing evidence has
indicated that non-cell-autonomous mechanisms are also involved,
requiring the presence of mutant SOD1 in neurons and glia [7–9],
although a recent study showed that neuronal expression of mutant
SOD1 is sufﬁcient to induce an ALS phenotype in transgenic mice [10].
The involvement of oxidative stress in the pathogenesis of ALS has
been described extensively, with oxidative damage to DNA, proteins,
and lipids within pathologically affected areas of the central nervous
system (CNS) [11–13], which is reproduced in animal and cell culture
models [14–16]. Although injurious in its own right, oxidative stress
can also exacerbate other mechanisms contributing to neurodegen-
eration in ALS [3,17–20]. Therefore, whether oxidative stress is a
primary cause of neurodegeneration, or merely a secondary conse-
quence of another toxic insult, the evidence suggests that it is a major
contributory factor leading to MN loss in ALS, making oxidative stress
an attractive therapeutic target. However, antioxidants have not
performed well in clinical trials [21,22], leading to the suggestion that
they may not be effective in ALS. A closer examination of published
reports suggests that may not be the case. The mutant SOD1 mouse
model [23] has long been considered the “gold standard” for
preclinical drug testing in ALS. However, 14 years after its develop-
ment, and with over 150 drugs tested, no treatment has successfully
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and the relevance of the mouse model to human ALS [24–26]. Given
that, a recent meta-analysis of drug treatment trials in the mutant
SOD1 mouse model of ALS concluded that antioxidant drugs have
been the most effective drug group in terms of extending survival
among animals treated at symptom onset [24]. The poor success of
antioxidants in clinical trials may also be partly due to failure to
achieve drug concentrations in the CNS sufﬁcient to have a
therapeutic effect. For example, trials of vitamin E, which does not
readily penetrate the CNS [27], have failed to show a robust beneﬁcial
effect in ALS even when administered at high dose [28].
If an antioxidant therapy is to progress beyond experimental
systems and move into the clinic, it is necessary to consider not only
the antioxidant capacity of the molecule, but also its physical and
chemical properties to obtain a concentration at the target cell
population sufﬁcient to achieve a worthwhile neuroprotective effect.
We have developed a systematic in vitro screening strategy for
identifying effective antioxidant molecules predicted to have the
ability to access the CNS, whichmay have a therapeutic beneﬁt for ALS
patients. Molecules that showed good efﬁcacy in the in vitro systems
were then screened in silico for their potential ability to successfully
enter the CNS, and the mechanism(s) by which they act were
investigated further. Three molecules, caffeic acid phenethyl ester
(CAPE), esculetin, and resveratrol, were identiﬁed as effective
antioxidants with the ability to increase the viability of a mutant
SOD1-expressing cell line and with biochemical properties indicating
they can penetrate the CNS.
Materials and methods
General laboratory reagents were from Sigma. Tissue culture
reagents were from Invitrogen, except fetal bovine serum (FBS), from
BioSera (Ringmer, East Sussex, UK). Tissue culture ﬂasks and plates
were from Greiner (Stonehouse, Gloucestershire, UK).
Cell culture
NSC34 mouse motor neuron cells [29] were maintained in DMEM
containing 10% fetal bovine serum (D10). NSC34 cells were trans-
fected with pIRESneo (Clontech, Saint-Germain, France) using
Lipofectamine 2000 (Invitrogen). Cells were transfected with empty
vector (pIRES cells) or pIRESneo containing wild-type human SOD1
(SOD1 cells) or one of four human SOD1mutants (G37R, H48Q, G93A,
and I113T cells). G418 (250 μg/ml) was added to cells 24 h later to
select for transfected cells. Single cell clones expressing comparable
levels of human SOD1, determined by Western blotting using sheep
anti-mouse SOD1 polyclonal antibody (Calbiochem, Nottingham, UK),
were selected.
Oxidative stress assay
NSC34 cells were grown in 96- or 384-well tissue-culture plates in
phenol red-freeD10until 30%conﬂuent. Oxidative stresswas inducedby
3 h serum withdrawal, in the presence or absence of compound.
Cytosolic reactive oxygen species levels were measured using dichloro-
ﬂuorescein (DCF) ﬂuorescence. Carboxy-H2DCFDA (6-carboxy-2′,7′-
dichlorodihydroﬂuorescein diacetate, di(acetoxymethyl ester);Molecu-
lar Probes, Paisley, UK) was added to NSC34 cells to 5 μM, and the
ﬂuorescence of oxidized DCF was read at Ex485 nm/Em530 nm after 1 h
using a Fusion universal plate reader (Packard BioScience, Beaconsﬁeld,
Buckinghamshire, UK). Cell death was simultaneously measured by
adding ethidium homodimer-1 (EthD1; 0.3 μM; Molecular Probes) to
the culture medium, and ﬂuorescence wasmeasured at Ex530 nm/Em645
nm. When different cell lines were compared, DCF results were
normalized to cell number, determined by measuring EthD1 ﬂuores-
cence after cells had been freeze–thawed. The Spectrum Collection(Microsource Discovery Systems, Gaylordsville, CT, USA) was screened
using NSC34 cells grown in black-walled 384-well plates using a Q-bot
liquid handling robot (Genetix, New Milton, Hampshire, UK). The
Spectrum Collection was stored in dimethyl sulfoxide (DMSO) at a
concentration of 5 mM. For experiments, DMSO stocks were diluted
directly in culture medium and all experiments included a DMSO
negative control containing equivalent concentrations of DMSO.
Cell viability assay
NSC34 cells were grown in 96-well plates in D10 until 60%
conﬂuent. Mediumwas replaced with freshmedium containing 10 μM
menadione, to induce oxidative stress [30], and Spectrum library
compound for 4 h. Cell viability was assessed using the MTT assay, as
described previously [31].
In silico screening
In silico screening was performed using SciTegic Pipeline Pilot
software (Accelrys, Cambridge, UK). The molecular polar surface area
(PSA) was calculated for all 2000 molecules from the Spectrum
Collection as a crude measure of likely CNS penetrance [32] and a
Lipinski ﬁlter was also applied to determine which molecules were
most drug-like. This ﬁlter applies the “Rule of 5” [33], which selects
molecules with a logPb5, molecular mass b500, b5 hydrogen bond
donors (OH+NH count), and b10 hydrogen bond acceptors (O+N
atoms).
Primary MN cultures
Primary MN cultures were established from E13.5 C57BL/6J mouse
embryos using established methods [34]. MN enrichment was
performed by layering the cell suspension onto a 6.4% iodixanol
cushion (Axis-Shield, Kimbolton, Cambridgeshire, UK) and centrifu-
ging at 500 g for 15 min. The MN-enriched fraction was plated onto
poly-D-ornithine/laminin-coated glass chamberslides at 12,000 cells/
cm2 in MNmedium (neurobasal medium containing B27 supplement,
2% horse serum, 1 ng/ml BDNF, 1 ng/ml GDNF, 5 ng/ml CNTF (growth
factors from R and D Systems, Abingdon, Oxon, UK)). After 24 h,
cultures were washed in phosphate-buffered saline (PBS) and then
incubated in MN mediumwithout growth factors or antioxidants, but
supplemented with 10 μM compound (or 0.2% DMSO as a vehicle
control). After a further 24 h, cultures werewashed in PBS and ﬁxed in
4% paraformaldehyde in PBS. Immunocytochemistry was performed
on cultures permeabilized in 0.1% Triton X-100 using SMI-31
(Sternberger Monoclonals, Baltimore, MD, USA) and rabbit anti-
peripherin (Chemicon International, Watford, Hertfordshire, UK)
primary antibodies and donkey anti-rabbit–Alexa Fluor 555 and
donkey anti-mouse–Alexa Fluor 488 (Invitrogen) secondary antibo-
dies. Nuclei were labeled using Hoechst 33342. The number of MNs
present in 20 random ﬁelds was counted for each culture using a 63×
oil emersion objective on a ﬂuorescence microscope.
Total radical-trapping antioxidant parameter (TRAP) assay
Radical-trapping antioxidant activity of compounds was tested
using a modiﬁcation to published methods [35]. The reaction mixture
consisted of 5 μM compound and 15 nM R-phycoerythrin (R-PE) in
75 mM phosphate buffer (pH 7.2). The oxidation reaction was started
by addition of 2,2′-azobis(2-methylpropionamidine) dihydrochloride
(AAPH) to a ﬁnal concentration of 50 mM. Decay of R-PE ﬂuorescence
was measured at Ex490 nm/Em580 nm 50 times, with a 1-min delay
between reads. Each compoundwas tested in eight wells and a control
without AAPH was also run to control for non-AAPH-mediated R-PE
decay. The average ﬂuorescence trace for the no-AAPH control was
subtracted from the average trace for each molecule tested to produce
Fig. 1. Mutant SOD1 induces oxidative stress in a motor neuron cell culture model. (a)
Western blot of NSC34 cell lysates, showing human SOD1 (upper band) and
endogenous murine SOD1 (lower band). (b) Basal oxidative stress levels measured
by quantiﬁcation of DCF ﬂuorescence in NSC34 cell lines expressing normal and mutant
human SOD1, normalized to cell number. Data shown are means±SEM. ANOVA
discovered signiﬁcant differences between treatments (p=1.3×10−7). There was no
signiﬁcant difference between any of the control cell lines (white bars), but all mutant
SOD1-expressing cells (gray bars) have higher intracellular ROS than control cells
(pb0.0001, Student's t test adjusted for false discovery rate).
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deﬁned as the last read at which the ﬂuorescence was equal to or
above the lower bound of a 95% conﬁdence interval for the mean
starting relative ﬂuorescence.
Antioxidant response element (ARE) reporter assay
Chinese hamster ovary cells stably expressing 4×ARE-TK-EGFP or
TK-EGFP reporter constructs (constructs kindly provided byWilliam E.
Fahl, University of Wisconsin [36]) were produced as described
elsewhere [37] and were maintained in D10. Conﬂuent cultures of
4×ARE-TK-EGFP- or TK-EGFP-expressing cells in 96-well tissue-
culture plates were treated with compound (0.01–100 μM) or vehicle
(DMSO) in FBS-free DMEM in triplicate for 24 h. EGFP ﬂuorescence
was then measured at Ex485 nm/Em530 nm.
5-Lipoxygenase activity assay
NSC34 cells were grown to 90% conﬂuency in a 24-well plate,
washed with PBS, and then incubated in 300 μl/well of DMEM
containing N2 supplement, 4 mM Hepes, 10 μM arachidonic acid, and
10 μM compound (or 0.2% DMSO as a control) for 3 h. Conditioned
medium was harvested, centrifuged to remove any cellular debris,
diluted 1:5 in DMEM, and assayed in triplicate for leukotriene B4
(LTB4) using an LTB4 ELISA (IDS Ltd., Boldon, Tyne and Wear, UK),
according to the manufacturer's instructions. Absorbance was mea-
sured at 405 nm.
NF-κB assay
NSC34 cells were grown to 90% conﬂuency and treated with 10 μM
compound for 1 h before addition of 10 μMmenadione for 5 min. Cells
were harvested in ice-cold PBS and nuclear lysates were prepared
using the NucBuster protein extraction kit (Novagen, Nottingham,
UK). Nuclear extracts (6 μg) were analyzed in triplicate for NF-κB
translocation using the NoShift II NF-κB transcription factor assay
(Novagen), according to the manufacturer's instructions.
Statistical analysis
Statistical analysis was performed using R (http://www.R-project.
org). In the initial library screen, “hits” were deﬁned as molecules
giving a DCF reading below the lower bound of a 99% prediction
interval (PI) for observations on the negative control. A 99% PI means
that if the experiment was repeated, 99% of negative controls would
be expected to fall within the prediction interval. The nonstandard
signiﬁcance level of 99% was used to make the screen more stringent.
Fluorescence readings from “blank” wells, containing medium and
carboxy-H2DCFDA, were subtracted from the raw data before
statistical analysis was performed. Further screening was done by
excluding toxic molecules, deﬁned as molecules giving an EthD1
reading above the upper bound of a 95% PI for observations on the
negative control (after subtraction of ﬂuorescence from blank wells
containing medium and EthD1, but no cells). To estimate EC50 values,
logistic curves were ﬁtted to the data and the relevant concentration
values were determined from the ﬁtted curves. If a molecule was toxic
at high concentration (based on EthD1 result), those concentrations
were removed before curve ﬁtting.
In the G93A-SOD1 assays, the data were checked for normality and
equal variance using the Shapiro–Wilk test of normality and Fligner–
Killeen test of equal variance. Where normality and equal variance
criteria were satisﬁed, the data were analyzed using ANOVA. For any
data for which the ANOVA assumptions were not satisﬁed, a
nonparametric test (Kruskal–Wallis) was used. In either case, hits
were deﬁned as molecules that signiﬁcantly reduced DCF ﬂuorescence
(pb0.05).For all other statistical analyses, the data were tested for normality
and equal variance as above. ANOVA was used when the data were
normally distributed, and if signiﬁcance was observed, pairwise
Student's t tests adjusted for multiple comparisons using the false
discovery rate modiﬁer [38] were used to determinewhich conditions
were signiﬁcantly different from the control. Otherwise, equivalent
nonparametric tests (Kruskal–Wallis test followed by pairwise
Wilcoxon tests adjusted for multiple comparisons) were used. All
pairwise comparisons were carried out using two-tailed statistical
tests. Statistical signiﬁcance was always considered as pb0.05.
Results
Development of a motor neuron cell culture model of mSOD1-mediated
ALS
An in vitro model of mSOD1-mediated ALS was established by
generating single cell clones of NSC34 motor neuron cells stably
expressing equivalent amounts of either normal human SOD1 or one
of four human SOD1 mutants associated with ALS (Fig. 1a). The SOD1
mutants used represent different classes of mutation: G37R retains
full dismutase activity but has reduced polypeptide stability [39];
H48Q has aberrant copper binding and little/no dismutase activity,
but does have a superoxide-dependent peroxidase activity, which
produces a powerful oxidant [40]; G93A has normal dismutase
activity but has increased free radical-generating function [41]; and
I113T has reduced dismutase activity [39] and decreased stability due
to changes at the dimer interface [42]. Because the precise mechanism
(s) by which mutant SOD1 triggers increased oxidative stress is as yet
unknown, we measured total oxidative stress by DCF ﬂuorescence.
Under basal culture conditions when oxidative stress levels were low,
expression of wild-type human SOD1 did not reduce oxidative stress
levels relative to untransfected or vector-transfected cells (Fig. 1b),
probably because SOD1 enzyme activity was not operating at its
maximum rate, so further increasing levels of wild-type SOD1 protein
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oxidative stress was signiﬁcantly increased in NSC34 cells expressing
any one of the four human SOD1 mutants compared to either wild-
type NSC34 cells or cells expressing pIRES vector or normal human
SOD1. Given that the SOD1 mutations used here all resulted in
increased levels of oxidative stress, this suggests that the increase was
not due to novel catalytic activity, but rather due to an unknown toxic
gain of function common to all mutants used. These results show that
this cell model reproduces the oxidative stress observed in other ALS
models and the human disease.
Simpliﬁed assay system for multiple testing
To efﬁciently screen large numbers of potential antioxidant
compounds, it was necessary to develop a simple cell-based oxidative
stress assay with a large window of effect. Short-term serum
withdrawal triggers an increase in oxidative stress in wild-type
NSC34 cells [43], which was seen as a threefold increase in DCF
ﬂuorescence (Figs. 2a–c). This increase in oxidative stress could be
rescued by ebselen (Fig. 2d), an organo-selenium antioxidant
compound previously shown to be protective against serum with-
drawal-induced death in mSOD1-expressing NSC34 cells [37]. Because
a reduction in DCF ﬂuorescence would also occur if ebselen induced
cell death through a mechanism not involving oxidative stress, a
simultaneous toxicity assay was also incorporated. EthD1 ﬂuoresces
when bound to DNA, but is not cell permeable and therefore
ﬂuoresces only when bound to DNA in a cell with a compromised
membrane. Ebselen reduced oxidative stress measured by DCF
ﬂuorescence without increasing EthD1 ﬂuorescence, indicating that
the reduced DCF ﬂuorescence was caused by a reduction in oxidative
stress (Fig. 2d). This simple assay system could then be used to screen
larger numbers of potential antioxidant molecules.Fig. 2. Oxidative stress can be induced in NSC34 cells by serum withdrawal. (a) DCF ﬂuores
Scale bar, 50 μm. (c) Serum withdrawal induced a threefold increase in DCF ﬂuorescence
withdrawal-induced oxidative stress, measured by DCF ﬂuorescence, in NSC34 cells in a dose
toxicity, as measured by EthD1 ﬂuorescence.Screening of known antioxidant molecules
Before expanding the assay to screen a compound library, a
targeted approach was adopted in which the literature was reviewed
for molecules, not present within the Spectrum Collection, that are
known to activate a variety of cellular antioxidant mechanisms. These
molecules were tested for their ability to reduce serum-withdrawal-
induced oxidative stress in NSC34 cells (Table 1). Each molecule was
tested at concentrations between 0.03 and 100 μM. The free radical
scavenger Trolox (a vitamin E analogue) was effective, whereas other
scavengers including the glutathione precursor 2-oxo-L-thiazolidine-
4-carboxylic acid (OTCA) and 4-hydroxy-2,2,6,6-tetramethylpiperi-
dine 1-oxyl (Tempol) failed to reduce serum withdrawal-induced
oxidative stress. Glutathione, vitamin C, and vitamin E were not tested
because they are all present within the Spectrum Collection. Another
free radical scavenger, α-lipoic acid, and the NADPH oxidase inhibitor
apocynin were also ineffective. The failure of apocynin was not
unexpected, because it is thought to act in glial cells rather than
neurons [4]. Other molecules found to be capable of reducing
oxidative stress in serum-withdrawn NSC34 cells include: ﬂupirtine,
which decreases mitochondrial free radical generation; the 5-
lipoxygenase antagonist nordihydroguaiaretic acid (NDGA); and the
anandamide transport inhibitor AM404. All of the molecules that
showed an antioxidant effect in serum-withdrawn NSC34 cells had
EC50 values between 1 and 10 μM and were capable of reducing the
oxidative stress by over 50% (Table 1).
Having identiﬁed molecules capable of reducing oxidative stress in
the simple cell assay, we then tested these molecules in the more
disease-relevant G93A-SOD1-expressing NSC34 cells to determine
whether they were effective against the oxidative stress induced by
the presence of mutant SOD1. Initially, antioxidant ability was tested
using DCF and EthD1 ﬂuorescence. Because the effective window wascence in wild-type NSC34 cells under basal conditions and (b) after serum withdrawal.
in wild-type NSC34 cells. Graph shows means±1 SEM. (d) Ebselen reduced serum
-dependent manner, with a half-maximal effect (EC50) of 4 μM. There was no increase in
Table 1
Known antioxidants tested in NSC34 oxidative stress and viability assays
Molecule Reported antioxidant activity EC50
(μM)
Max % DCF
decrease
Protective in
G93A cells?
ALS-speciﬁc ﬁndings
Basal DCF MTT
N-(4-hydroxyphenyl)arachidonoyl
ethanolamide (AM404)
Anandamide transport inhibitor, biochemical
antioxidant [77]
4 80 Yes Yes Not found
Apocynin Inhibits NADPH oxidase — — ND ND Increased SOD1G93A mouse survival [4]
Flupirtine Decreases mitochondrial free radical
generation [78]
7 67 No ND Not found
α-Lipoic acid Activates Nrf2 [79]; scavenges ROS — — ND ND Increased SOD1G93A mouse survival [80]
Nordihydroguaiaretic acid 5-Lipoxygenase antagonist [53] 4 108 Yes Yes Increased SOD1G93A mouse survival [53]
2-Oxo-L-thiazolidine-4-carboxylic acid (OTCA) Cell-permeative glutathione precursor [57] — — ND ND Not found
4-Hydroxy-2,2,6,6-tetramethylpiperidine
1-oxyl (Tempol)
Free radical scavenger [81] — — ND ND Not found
Trolox ((±)-6-hydroxy-2,5,7,
8-tetramethylchromane-2-carboxylic acid)
Water-soluble vitamin E analogue
(ROS scavenger) [82]
1 79 Yes No Increased viability of SOD1G93A-expressing
motor neuron cell line [82]
Molecules were considered to be protective in G93A-NSC34 cells if they signiﬁcantly reduced basal oxidative stress or increased viability after 10 μMmenadione treatment (by MTT)
at concentrations up to 10 μM (pb0.05, ANOVA). ND, not determined.
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at low micromolar concentrations were of interest, G93A-SOD1-
expressing cells were treatedwith concentrations of eachmolecule up
to 10 μM under basal conditions for 4–6 h and DCF ﬂuorescence was
measured as before. Flupirtine was unable to reduce oxidative stress
caused by G93A-SOD1, whereas Trolox, NDGA, and AM404 were still
effective (Table 1).
To validate these results in a different assay system that did not
involve DCF ﬂuorescence, the three molecules that were effective in
reducing G93A-SOD1-mediated oxidative stress were then tested for
their ability to increase viability of G93A-SOD1-expressing NSC34 cells
exposed to a further oxidative stress. This additional oxidative stress
was induced using the quinone-containing compound menadione,
which undergoes one-electron reduction to produce semiquinone
radicals, which react with molecular oxygen to generate reactive
oxygen species [30]. After menadione treatment, cell viability was
assessed by MTT assay. Treatment with 10 μM menadione for 4 h
reduced viability to 10–20% of controls, and this could be rescued only
by NDGA and AM404 (Table 1).
Screening of Spectrum Collection in NSC34 cells
Having developed an in vitro screening cascade capable of
identifying molecules that reduce oxidative stress and increase
viability of motor neuron cells expressing an ALS-associated mutant
of SOD1, we used the methodology to screen the Spectrum Collection
of 2000 molecules. This collection consists of the National Institute of
Neurological Disorders and Stroke (NINDS) Custom Collection, pure
natural products, and a small number of endocrine disruptors and
toxic substances. The initial library screen was performed using the
simple serum-withdrawal oxidative stress in wild-type NSC34 cells.
Each molecule was tested at 10 μM on two separate occasions. Vehicle
(0.2% DMSO) and 10 μM ebselen were used as negative and positive
controls, respectively. Hits were deﬁned as molecules that gave a DCF
ﬂuorescence of less than the lower bound of a 99% PI for observations
on the negative control. Using this threshold, over 98% of positive
controls were successfully identiﬁed as hits. A molecule was deﬁned
as toxic if it gave an EthD1 ﬂuorescence of greater than the upper
bound of a 95% PI for observations on the negative control. Using these
criteria, 164 molecules were identiﬁed as hits in both runs of the
library. The results from a typical 384-well plate are shown in Fig. 3a.
The 164 molecules (and DMSO vehicle) were next tested for their
ability to reduce DCF ﬂuorescence in serum-withdrawn NSC34 cells at
ﬁve concentrations (1, 3, 10, 30, and 100 μM) in duplicate. Toxicity was
again tested by measuring EthD1 ﬂuorescence. A result of toxicity was
returned for any concentration at which both wells gave an EthD1
ﬂuorescence greater than the upper bound of a 95% PI for observationson the negative control. The DMSO vehicle control was not toxic even
at the highest concentration tested (2%). The DCF ﬂuorescence was
plotted for each molecule at all concentrations for which toxicity was
not observed. No dose response was seen for 42 molecules (and
DMSO). For the remaining 122 molecules, the maximum percentage
decrease in DCF ﬂuorescence was calculated, and the concentration
that produced a 50% effect (EC50) was estimated by interpolation
using a ﬁtted logistic curve. Representative dose–response curves are
shown in Fig. 3b.
Molecules with the potential to be used as antioxidants in vivo
must be capable of reducing oxidative stress at low concentration
without causing toxicity. To identify such molecules, the data were
analyzed in two ways and the molecules were ranked according to
two different parameters: (1) antioxidant ability (measured by DCF
reduction), regardless of concentration, and (2) index of efﬁcacy
relative to toxicity, which considered the window between an
effective dose and a toxic dose. This index was produced by dividing
the lowest concentration that showed toxicity (for molecules for
which toxicity was not seen at the highest concentration tested,
toxicity was assumed to be present at the next concentration on the
dose curve) by the estimated EC50 value. A high value would
correspond to a large window between the EC50 and toxicity. Plotting
the antioxidant ability against the index of efﬁcacy relative to toxicity
provided a way to identify the molecules that scored well on both
measures. Forty-ﬁve molecules were identiﬁed as hits that gave a DCF
decrease of at least 40% and an index of efﬁcacy to toxicity of over 30
(Fig. 3c). Six further molecules were also selected because they gave
estimated EC50 values of below 5 μM, and it was considered possible
that these molecules could be effective at very low concentrations.
These 51 compounds were retested over a more comprehensive
concentration range between 0.01 and 100 μM in triplicate. Clear
dose–response curves with EC50 values below 10 μM were produced
by 47 molecules. All molecules that failed showed an effect only at 30
or 100 μM, which was considered to be too high to be of potential
therapeutic beneﬁt.
Validation of hits in G93A-SOD1-expressing cells
The remaining 47 molecules were then tested in NSC34 cells
expressing G93A-SOD1, which showed increased oxidative stress
under basal conditions. The cells were treated with three concentra-
tions of eachmolecule (0.1,1, and 10 μM) under basal conditions for 4–
6 h and DCF and EthD1 ﬂuorescence was measured as before. Twenty
molecules signiﬁcantly reduced basal DCF ﬂuorescence in a nontoxic
manner in G93A-SOD1 NSC34 cells. Of these, 8 reduced DCF
ﬂuorescence in G93A-expressing cells to less than 50% of basal DCF
ﬂuorescence at a concentration of 10 μM.
Fig. 3. Summary of screening results in NSC34 cells. (a) Results from a typical 384-well
plate of NSC34 cells used to screen the Spectrum Collection. The solid line shows the
midpoint (mean) between the negative (vehicle, 0.2% DMSO) and the positive control
(10 μM ebselen), and the broken line shows the threshold of the lower bound of a 99%
prediction interval for observations on the negative control. All molecules giving a DCF
ﬂuorescence value below this broken line were classiﬁed as hits (provided no toxicity
was observed by EthD1 ﬂuorescence). (b) Representative dose–response curves from
two molecules. Dotted lines show the concentration giving the half-maximal effect
(EC50). (c) Plotting % reduction in DCF versus minimum toxic dose/EC50 shows which
molecules are effective antioxidants with a largewindow between an effective dose and
a toxic dose. Cutoff points of below a 40% reduction in DCF ﬂuorescence and below a
toxicity/EC50 of 30 produced 45 hits, shown in the top-right quadrant.
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described above were then tested for their ability to increase viability
of G93A-SOD1-expressing NSC34 cells exposed to a further oxidative
stress. Treatment with 10 μM menadione for 4 h reduced viability to
10–20% of controls, and this could be signiﬁcantly rescued by 14 of the
20molecules tested. Therefore, thesemolecules not only were capable
of reducing oxidative stress, but also could increase viability in
oxidatively stressed cells. Of these, 3 doubled the viability of
menadione-treated G93A cells, and another 6 increased viability byat least 50%. Three of these top-performing molecules were also in the
top-performing molecules in the basal oxidative stress assay. Ebselen,
which is represented within the Spectrum Collection, was one of the 6
compounds that was effective in the DCF assays, but failed to
signiﬁcantly increase the survival of menadione-treated NSC34 cells.
A review of the literature showed that 9 of the 14 effective compounds
have been found to be tolerated in mammalian in vivo systems. These
9 compounds, shown in Fig. 4, formed the hits from the in vitro
screening of the Spectrum library. The results of each of these
molecules for each stage of the screening process are summarized in
Table 2.
In silico analysis
The biochemical structures of the nine hits were analyzed using
SciTegic Pipeline Pilot software to identify the molecules with “drug-
like” properties (Table 2). Six molecules passed the Rule of 5, which
states that most drug-like molecules have a molecular weight of 500
or less, a logP value (octanol/water partition coefﬁcient; a measure of
molecular hydrophobicity) of 5 or less, up to 5 hydrogen bond donors,
and up to 10 hydrogen bond acceptors [33]. The molecular PSA of a
molecule is a predictor for blood–brain barrier (BBB) penetration [32],
with the majority of orally administered CNS-active drugs that
penetrate the BBB passively having a PSA of below 70 Å2 and virtually
all having a PSA below 120 Å2 [44]. Three of the molecules that passed
the Rule of 5 had a PSA of less than 70 Å2.
The three compounds that passed these criteria were resveratrol,
esculetin, and CAPE (Fig. 4a). All three molecules have previously
been identiﬁed as having antioxidant activity [45–50]. Of the six
remaining molecules, three passed the Rule of 5 but had PSA values
above 70 Å2 (Fig. 4b) and three failed both the Rule of 5 and the PSA
criteria (Fig. 4c), making them less likely to be effective in vivo, and
were therefore not studied further. In silico analysis of the molecules
identiﬁed in the screen of known antioxidants showed that NDGA
passed the Rule of 5, but had a molecular PSA of 80.9 Å2, whereas
AM404 failed the Rule of 5. Because neither of these molecules
passed the in silico criteria, they were not taken forward for further
study. The compounds taken forward from the in vitro screen of the
Spectrum Collection were resveratrol, esculetin, and CAPE. Typical
results for each of these molecules from each stage of the screening
process are shown in Fig. 5.
Primary MN assay
Having identiﬁed molecules capable of rescuing oxidative stress
associatedwith G93A-SOD1 in amotor neuron cell line, we then tested
the molecules for their ability to support survival of primary MN
cultures in which oxidative stress had been induced by trophic factor
withdrawal [51]. PrimaryMNs were cultured frommouse embryos for
24 h, after which trophic factors and antioxidants were withdrawn for
a further 24 h. Cultures deprived of trophic factors and antioxidants
showed signiﬁcantly decreased viability, as assessed by counting the
number of survivingMNs in 20 randomﬁelds (42.75±6.25% of control
cultures (mean±SEM), p=0.007, Wilcoxon test). Addition of either
CAPE or esculetin at 10 μM signiﬁcantly increased MN viability
(p=0.014 and 0.020, respectively; Fig. 6). Neither resveratrol nor
ebselen was capable of increasing MN viability.
Mechanism of action of best-hit molecules
Because the best-hit molecules were identiﬁed through assays
measuring total oxidative stress and viability, it was not known how
they were acting. To investigate whether the best-hit molecules act
through a commonmechanism or activate diverse pathways the effect
of each compound was tested on several classical antioxidant
pathways.
Fig. 4. Chemical structures of Spectrum library compounds that had a signiﬁcant effect in all four in vitro screens and can be tolerated in vivo. Compounds are subdivided according to
their predicted biochemical properties (Table 2). (a) Compounds satisfying Lipinski's Rule of 5 for an orally available drug and with a polar surface area (PSA) of b70 Å2. Compounds
(b) with a high PSA or (c) that failed the Rule of 5 were not taken further.
1133S.C. Barber et al. / Free Radical Biology & Medicine 46 (2009) 1127–1138Free radical buffering
To determine the ability of each molecule to scavenge free radicals,
the TRAP was measured relative to 6-hydroxy-2,5,7,8-tetramethyl-
chroman-2-carboxylic acid (Trolox; a water-soluble analogue ofTable 2
Summary of best-hit molecules from screen in NSC34 cells and their in silico properties
Molecule Serum-withdrawn NSC34 G93A cells
EC50 (μM) Max % DCF decrease DCF (% of basal) M
Resveratrol 4 54 72 13
Esculetin 1 80 −7 19
Caffeic acid phenethyl ester 2 94 36 25
Quercetin 5 43 15 16
Morin 14 123 33 12
Dipyrone 1 75 61 12
Epicatechin pentaacetate 5 95 62 15
Chlorogenic acid 0.6 50 67 13
Quercitrin 0.9 43 74 12
Rule of 5 and molecular polar surface area calculations were performed using Pipeline Pilo
number of hydrogen bond donors; H acceptor, number of hydrogen bond acceptors; PSA, pvitamin E) [35]. R-PE ﬂuorescence decays in the presence of free
radicals produced by controlled decomposition of AAPH. Free radical
scavengers can buffer the radicals produced from the decomposition
of AAPH and delay the decay of R-PE. The length of the lag time beforeMW LogP H donor H acceptor Rule of 5 PSA (Å2)
TT (% of control)
4 228.3 3.09 3 3 Pass 60.68
3 178.1 1.42 2 4 Pass 66.76
4 284.3 3.57 2 4 Pass 66.76
0 302.2 1.63 5 7 Pass 127.45
8 302.2 1.63 5 7 Pass 127.45
2 333.3 0.38 1 7 Pass 150.36
9 500.5 2.44 0 11 Fail 140.72
4 354.3 -0.34 6 9 Fail 164.75
4 448.4 0.59 7 11 Fail 186.37
t software. MW, molecular weight; LogP, octanol/water partition coefﬁcient; H donor,
olar surface area (Å2).
Fig. 5. Summary of the performances of the topmolecules in the in vitro screening experiments. (a) NSC34 serum-free dose–response curves. (b) G93A-SOD1 NSC34 basal DCF assay
results (mean + SEM). Where a negative result is shown, the DCF ﬂuorescence was reduced to levels below background ﬂuorescence levels in blank wells containing medium and
carboxy-H2DCFDA, but no cells. (c) G93A-SOD1 NSC34 menadione MTT viability assay results (mean+SEM).
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scavenging ability. To control for the bleaching of R-PE ﬂuorescence
by repeated excitation, relative ﬂuorescence was calculated by
subtracting the R-PE ﬂuorescence in the absence of AAPH. Each of
the best-hit molecules and ebselen were tested in this assay, along
with Trolox as a positive control. Typical traces from the TRAP assay
are shown in Fig. 7a. Of the molecules tested, only esculetin
signiﬁcantly delayed decay of R-PE, suggesting that only esculetinFig. 6. Effects of the best-hit molecules on survival of primary mouse motor neurons
deprived of growth factors. Results show the mean numbers of motor neurons±SEM
counted in 20 random ﬁelds from four cultures. All conditions used medium without
growth factors or antioxidants, except “Complete,” which contained complete motor
neuron medium, as deﬁned under Materials and methods. ⁎p=0.020, ⁎⁎p=0.014
(Wilcoxon test, adjusted for false discovery rate, after signiﬁcant results from a Kruskal–
Wallis test (p=0.0005)).can directly buffer free radicals (p=0.0051, Wilcoxon test, Fig. 7b).
The other hit molecules must therefore be acting through cellular
antioxidant pathways.
Induction of antioxidant response element
We have previously shown that NSC34 cells expressing G93A-
SOD1 have down-regulated a number of “programmed cell life” genes,
the expression of which is regulated by the transcription factor Nrf2
(nuclear factor erythroid 2-related factor 2) acting through the ARE
[52]. Using a GFP reporter assay, we found that ebselen, the positive
control in the library screen, can induce transcription of genes under
the control of the ARE [37]. We therefore used this assay system to
determine whether any of the best-hit molecules identiﬁed in the
library screen act through the ARE pathway. Only CAPE induced
transcription of GFP under the control of the ARE, with an EC50 of
9.5 μM (p=0.0022; Student's t test, Figs. 7c and d). CAPE did not
increase GFP ﬂuorescence in the control TK-ARE-expressing cells,
showing that increased GFP production required the ARE. Resveratrol
and esculetin did not increase GFP ﬂuorescence.
Inhibition of 5-lipoxygenase
There is increasing evidence for the role of the proinﬂammatory
eicosanoid LTB4 in G93A-SOD1-mediated ALS, with increased levels
reported in G93A-SOD1 mouse spinal cord [53] and cultured
astrocytes [54]. Given that LTB4 can increase reactive oxygen species
production [55] and NDGA, an inhibitor of 5-lipoxygenase (5-LOX)-
mediated LTB4 production, reduced oxidative stress in NSC34 cells as
well as increasing survival of G93A-SOD1 mice [53], we investigated
whether any of the best-hit molecules were affecting 5-LOX activity.
NSC34 cells were treated with 10 μM arachidonic acid in the presence
and absence of 10 μM compound for 3 h before the culture medium
was harvested and analyzed for LTB4. Resveratrol, esculetin, and
ebselen were all found to signiﬁcantly inhibit LTB4 production from
Fig. 7. Cellular pathways activated by best-hit molecules. (a) Typical traces from TRAP assay. There was a 1-min delay between each reading of the plate. (b) Summary of TRAP
assay results, showing that of the best-hit molecules tested, only esculetin signiﬁcantly delayed decay of R-PE (p=0.0051 for both esculetin and Trolox, Wilcoxon test). (c) Typical
dose–response curves for the effect of CAPE on induction of 4×ARE-TK-EGFP (solid line) and TK-EGFP (broken line). (d) Summary of the induction of ARE-TK-EGFP. Only CAPE
signiﬁcantly induced ARE-mediated gene transcription (p=0.0022; Student's t test). (e) 5-LOX activity assay. Resveratrol, esculetin, and ebselen all signiﬁcantly reduced LTB4
synthesis by 5-LOX (p=0.0028, 0.014, and 0.028, respectively; Student's t test). (f) NF-κB activation assay. Menadione (10 μM) induced translocation of NF-κB to the nucleus
(white bar). This translocation could be signiﬁcantly inhibited by CAPE, esculetin, and ebselen (p=0.00021, 0.0013, and 0.031, respectively; Wilcoxon test). All results shown are
means±SEM. All pairwise tests were performed only after statistical signiﬁcance was discovered with the appropriate combined test (ANOVA or Kruskal–Wallis) and were
adjusted for multiple comparisons.
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t test), whereas CAPE had no effect on LTB4 levels (Fig. 7e). This result
contrasts with a report describing CAPE as a 5-LOX inhibitor in mouse
peritoneal macrophages [56].
Inhibition of NF-κB
Oxidative stress can activate the transcription factor NF-κB, leading
to further cellular stress, and CAPE has previously been described as
an inhibitor of NF-κB activation [49]. To investigate whether CAPE
and/or any of the other best-hit molecules acts through inhibition of
NF-κB, NSC34 cells were pretreated with each compound for 1 h
before oxidative stress was induced by 10 μM menadione. NF-κB
translocation was increased by over 2.5-fold by menadione
(p=0.00021) and was partly inhibited by CAPE, esculetin, andebselen (p=0.00021, 0.0013, and 0.031, respectively; Wilcoxon test,
Fig. 7f).
Discussion
We have used an in vitro screening cascade to assay the Spectrum
Collection of 2000 compounds and several known candidate anti-
oxidant compounds for their ability to reduce serum withdrawal-
induced oxidative stress in amotor neuron cell line. The hits have been
further reﬁned in subsequent assays of oxidative stress and viability in
motor neuron cells expressing an ALS-associated SOD1 mutation
(G93A), and compounds likely to be able to access the CNS were
selected based on their predicted biochemical properties. The most
attractive compounds, resveratrol, esculetin, and CAPE, were then
1136 S.C. Barber et al. / Free Radical Biology & Medicine 46 (2009) 1127–1138tested for their ability to rescue primary MNs from trophic factor
withdrawal-induced oxidative stress and cell death. Although these
molecules were all capable of reducing oxidative stress, they seemed
to be acting via different mechanisms.
The Spectrum Collection consists of the NINDS Custom Collection,
a selection of pure natural products and a small number of endocrine
disruptors and toxic substances. The NINDS collection includes 640
drugs approved by the Food and Drug Administration, drugs that have
reached late-phase human trials, and drugs likely to affect CNS
function. Such a collection provides both structural and biological
diversity for screening programs. Any hits in approved drugs should
have a rapid route to the clinic, because they are known to be drug-like
and safe in humans, whereas natural products are a potentially rich
source of antioxidants and have provided the starting points for many
approved drugs throughout the history of drug development.
Although many of the hits from the initial library screen have
previously been described as antioxidants, other molecules not
previously recognized as having antioxidant activity were also
identiﬁed. Perhaps of more interest, some well-characterized anti-
oxidants present within the library, including glutathione and
vitamins C (ascorbic acid) and E (α-tocopherol), were not identiﬁed
as hits. This may be because they failed to reach the site of oxidative
stress at concentrations sufﬁcient to have an effect. The ability of
glutathione to cross plasma membranes is limited, which may
account for its poor performance in the library screen. However,
OTCA, a cell-permeative precursor of glutathione [57], tested as one
of the known antioxidant molecules, also failed to rescue NSC34 cells
from serum withdrawal-induced oxidative stress, although whether
OTCA treatment leads to increased glutathione levels in NSC34 cells
was not determined (Table 1). Similarly, vitamin E is a potent
antioxidant, but it is highly lipid-soluble and therefore tends to
partition into lipid-rich compartments, such as the plasma mem-
brane, where it may be unable to buffer cytosolic free radicals. In
support of this, the water-soluble vitamin E analogue Trolox was
capable of reducing cytosolic oxidative stress. Although vitamin C has
antioxidant activity, many previous in vitro studies have found it to
be unable to reduce oxidative stress [58,59] or used much higher
doses than the 10 μM used in the Spectrum library screen [60–62].
Alternatively, the failure of such free radical buffers may indicate that
direct buffering of free radicals is not sufﬁcient to rescue the toxic
gain of function caused by mutant SOD1 in ALS. This is further
supported by considering that of the best-hit molecules, only
esculetin was capable of directly buffering free radicals. Esculetin is
one of at least 12 coumarins or coumarin derivatives in the Spectrum
library, but was the only one to be identiﬁed as a hit in the initial
screen, even though fraxetin, another coumarin present within the
library, has been shown to be more potent at scavenging superoxide
[63]. This suggests that the protective effects of esculetin observed
may be mediated via cellular signaling pathways and again supports
the hypothesis that free radical buffering may be insufﬁcient to
rescue oxidatively stressed NSC34 cells.
The best-performing molecules identiﬁed from the Spectrum
library screen, resveratrol, esculetin, and CAPE, have all previously
been identiﬁed as naturally occurring antioxidants [45–48,64].
Resveratrol is found in red wine, esculetin is present in tobacco
leaves, and CAPE is an active component of the bee product propolis.
In NSC34 cells, each of these molecules was capable of activating
antioxidant cellular pathways (Fig. 7). Resveratrol initially seemed to
be an attractive compound, with extensive in vitro and in vivo studies
reviewed elsewhere [45]. However, the subsequent assays showed
resveratrol to be less effective than either esculetin or CAPE, and a
review of the literature showed that although the in vitro studies have
mostly been successful, they often require high doses of resveratrol
and in vivo studies have shown rapid metabolism and failed to detect
resveratrol in the CNS [65]. Taken together, this suggested that
resveratrol is unlikely to be effective in vivo.Esculetin and CAPE performed comparably in the in vitro screen-
ing, and both activated a variety of, albeit different, cellular pathways.
Both esculetin and CAPE inhibited NF-κB activation, and esculetin also
inhibited 5-LOX, representing two pathways that when activated lead
to inﬂammation [66,67]. CAPE was also able to activate the Nrf2–ARE
pathway (Figs. 7c and d), a pathway we have previously shown to be
down-regulated in NSC34 cells expressing mutant SOD1 and MNs
isolated from cases of familial SOD1-associated ALS [52]. The
structure of CAPE, including a hydrophobic/aromatic moiety with a
hydroxyl group, is consistent with known Nrf2 activators, which are
thought to react with Keap1 (Kelch ECH-associating protein 1; the
cytoplasmic Nrf2 regulator), thereby releasing Nrf2 for translocation
to the nucleus [68]. Genes up-regulated by Nrf2 include the
antioxidants glutathione peroxidase, glutathione reductase, and
heme oxygenase 1; enzymes involved in glutathione synthesis; and
NADPH-regenerating enzymes [69,70].
There are multiple reports showing beneﬁcial effects of both
esculetin [47] and CAPE [50,71–73] in vivo, although only CAPE has
shown positive effects in the CNS. There is evidence to suggest that
esculetin is efﬁciently removed by the liver [74] and thereforemay not
achieve levels sufﬁcient to be effective in the CNS. CAPE has been
shown to be well absorbed into plasma after oral administration [75],
and although itwas found to have a short half-life in rat plasma in vitro,
it was metabolized to caffeic acid [76], which was also effective in
serum-withdrawn NSC34 cells and showed a positive trend when
tested in G93A-SOD1-expressing cells. Other caffeic acid derivatives
were also identiﬁed in the initial library screen, including chlorogenic
acid and rosmarinic acid (effective in NSC34 cells, but failed to reach
statistical signiﬁcance in G93A-SOD1-expressing cells), suggesting
that metabolites of CAPE may still be effective in vivo. Taken together
with theﬁnding that the half-life of CAPE in humanplasma in vitrowas
more sustained than in rat plasma [76], this makes CAPE an attractive
candidate to take forward for in vivo studies. We are now currently
investigating the pharmacokinetic proﬁle of the best-hit molecules in
mice, with the intention of progressing to studies of disease-modifying
effects in the murine G93A-SOD1 transgenic model of ALS.
Acknowledgments
This work was funded by a program award from the Wellcome
Trust. The TK-GFP constructs were provided by William E. Fahl
(University of Wisconsin). We gratefully acknowledge Karen Holland
(University of Shefﬁeld) for her help with the robot and John Holliday
(Department of Chemistry, University of Shefﬁeld) for his assistance
with the in silico analysis.
References
[1] Rosen, D. R.; Siddique, T.; Patterson, D.; Figlewicz, D. A.; Sapp, P.; Hentati, A.;
Donaldson, D.; Goto, J.; O'Regan, J. P.; Deng, H. X.; Rahmani, Z.; Krizus, A.;
McKenna-Yasek, D.; Cayabyab, A.; Gaston, S. M.; Berger, R.; Tanzi, R. E.;
Halperin, J. J.; Herzfeldt, B.; Van den Bergh, R.; Hung, W.; Bird, T.; Deng, G.;
Mulder, D. W.; Smyth, C.; Laing, N. G.; Soriano, E.; Pericak-Vance, M. A.; Haines,
J.; Rouleau, G. A.; Gusella, J. S.; Horvitz, H. R.; Brown Jr., R. H. Mutations in Cu/
Zn superoxide dismutase gene are associated with familial amyotrophic lateral
sclerosis. Nature 362:59–62; 1993.
[2] Shaw, P. J. Molecular and cellular pathways of neurodegeneration in motor
neurone disease. J. Neurol. Neurosurg. Psychiatry 76:1046–1057; 2005.
[3] Barber, S. C.; Mead, R. J.; Shaw, P. J. Oxidative stress in ALS: a mechanism of
neurodegeneration and a therapeutic target. Biochim. Biophys. Acta
1762:1051–1067; 2006.
[4] Harraz, M. M.; Marden, J. J.; Zhou, W.; Zhang, Y.; Williams, A.; Sharov, V. S.; Nelson,
K.; Luo, M.; Paulson, H.; Schoneich, C.; Engelhardt, J. F. SOD1 mutations disrupt
redox-sensitive Rac regulation of NADPH oxidase in a familial ALS model. J. Clin.
Invest. 118:659–670; 2008.
[5] Nishitoh, H.; Kadowaki, H.; Nagai, A.; Maruyama, T.; Yokota, T.; Fukutomi, H.;
Noguchi, T.; Matsuzawa, A.; Takeda, K.; Ichijo, H. ALS-linked mutant SOD1 induces
ER stress- and ASK1-dependent motor neuron death by targeting Derlin-1. Genes
Dev. 22:1451–1464; 2008.
[6] Polymenidou, M.; Cleveland, D. W. Motor neuron disease: the curious ways of ALS.
Nature 454:284–285; 2008.
1137S.C. Barber et al. / Free Radical Biology & Medicine 46 (2009) 1127–1138[7] Gong, Y. H.; Parsadanian, A. S.; Andreeva, A.; Snider, W. D.; Elliott, J. L. Restricted
expression of G86R Cu/Zn superoxide dismutase in astrocytes results in
astrocytosis but does not cause motoneuron degeneration. J. Neurosci.
20:660–665; 2000.
[8] Lino, M. M.; Schneider, C.; Caroni, P. Accumulation of SOD1 mutants in
postnatal motoneurons does not cause motoneuron pathology or motoneuron
disease. J. Neurosci. 22:4825–4832; 2002.
[9] Pramatarova, A.; Laganiere, J.; Roussel, J.; Brisebois, K.; Rouleau, G. A. Neuron-
speciﬁc expression of mutant superoxide dismutase 1 in transgenic mice does not
lead to motor impairment. J. Neurosci. 21:3369–3374; 2001.
[10] Jaarsma, D.; Teuling, E.; Haasdijk, E. D.; De Zeeuw, C. I.; Hoogenraad, C. C.
Neuron-speciﬁc expression of mutant superoxide dismutase is sufﬁcient to
induce amyotrophic lateral sclerosis in transgenic mice. J. Neurosci. 28:
2075–2088; 2008.
[11] Shaw, P. J.; Ince, P. G.; Falkous, G.; Mantle, D. Oxidative damage to protein in
sporadic motor neuron disease spinal cord. Ann. Neurol. 38:691–695; 1995.
[12] Beal, M. F.; Ferrante, R. J.; Browne, S. E.; Matthews, R. T.; Kowall, N. W.; Brown Jr.,
R. H. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral
sclerosis. Ann. Neurol. 42:644–654; 1997.
[13] Fitzmaurice, P. S.; Shaw, I. C.; Kleiner, H. E.; Miller, R. T.; Monks, T. J.; Lau, S. S.;
Mitchell, J. D.; Lynch, P. G. Evidence for DNA damage in amyotrophic lateral
sclerosis. Muscle Nerve 19:797–798; 1996.
[14] Ferrante, R. J.; Shinobu, L. A.; Schulz, J. B.; Matthews, R. T.; Thomas, C. E.; Kowall, N.
W.; Gurney, M. E.; Beal, M. F. Increased 3-nitrotyrosine and oxidative damage in
mice with a human copper/zinc superoxide dismutase mutation. Ann. Neurol.
42:326–334; 1997.
[15] Andrus, P. K.; Fleck, T. J.; Gurney, M. E.; Hall, E. D. Protein oxidative damage in a
transgenic mouse model of familial amyotrophic lateral sclerosis. J. Neurochem.
71:2041–2048; 1998.
[16] Menzies, F. M.; Cookson, M. R.; Taylor, R. W.; Turnbull, D. M.; Chrzanowska-
Lightowlers, Z. M. A.; Dong, L.; Figlewicz, D. A.; Shaw, P. J. Mitochondrial
dysfunction in a cell culture model of familial amyotrophic lateral sclerosis. Brain
125:1522–1533; 2002.
[17] Rao, S. D.; Weiss, J. H. Excitotoxic and oxidative cross-talk between motor neurons
and glia in ALS pathogenesis. Trends Neurosci. 27:17–23; 2004.
[18] Rao, S. D.; Yin, H. Z.; Weiss, J. H. Disruption of glial glutamate transport by reactive
oxygen species produced in motor neurons. J. Neurosci. 23:2627–2633; 2003.
[19] Trotti, D.; Rolfs, A.; Danbolt, N. C.; Brown Jr., R. H.; Hediger, M. A. SOD1 mutants
linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate
transporter. Nat. Neurosci. 2:427–433; 1999.
[20] Rakhit, R.; Cunningham, P.; Furtos-Matei, A.; Dahan, S.; Qi, X. F.; Crow, J. P.;
Cashman, N. R.; Kondejewski, L. H.; Chakrabartty, A. Oxidation-induced misfold-
ing and aggregation of superoxide dismutase and its implications for amyotrophic
lateral sclerosis. J. Biol. Chem. 277:47551–47556; 2002.
[21] Desnuelle, C.; Dib, M.; Garrel, C.; Favier, A. A double-blind, placebo-controlled
randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of
amyotrophic lateral sclerosis. ALS Riluzole–Tocopherol Study Group. Amyotroph.
Lateral Scler. Other Motor Neuron Disord. 2:9–18; 2001.
[22] Orrell, R.; Lane, R.; Ross, M., Antioxidant treatment for amyotrophic lateral
sclerosis/motor neuron disease. Cochrane Database Syst. Rev. CD002829; 2007.
[23] Gurney, M. E.; Pu, H.; Chiu, A. Y.; Dal Canto, M. C.; Polchow, C. Y.; Alexander, D. D.;
Caliendo, J.; Hentati, A.; Kwon, Y. W.; Deng, H. X.; Chen, W. J.; Zhai, P.; Suﬁt, R. L.;
Siddique, T. Motor neuron degeneration in mice that express a human Cu,Zn
superoxide dismutase mutation. Science 264:1772–1775; 1994.
[24] Benatar, M. Lost in translation: treatment trials in the SOD1 mouse and in human
ALS. Neurobiol. Dis. 26:1–13; 2007.
[25] Scott, S.; Kranz, J. E.; Cole, J.; Lincecum, J. M.; Thompson, K.; Kelly, N.; Bostrom, A.;
Theodoss, J.; Al-Nakhala, B. M.; Vieira, F. G.; Ramasubbu, J.; Heywood, J. A. Design,
power, and interpretation of studies in the standard murine model of ALS.
Amyotroph. Lateral Scler. 9:4–15; 2008.
[26] Schnabel, J. Neuroscience: Standard model. Nature 454:682–685; 2008.
[27] Pappert, E. J.; Tangney, C. C.; Goetz, C. G.; Ling, Z. D.; Lipton, J. W.; Stebbins, G. T.;
Carvey, P. M. Alpha-tocopherol in the ventricular cerebrospinal ﬂuid of Parkinson's
disease patients: dose–response study and correlations with plasma levels.
Neurology 47:1037–1042; 1996.
[28] Graf, M.; Ecker, D.; Horowski, R.; Kramer, B.; Riederer, P.; Gerlach, M.; Hager, C.;
Ludolph, A. C.; Kramer, B.; Ecker, D.; Becker, G.; Osterhage, J.; Jost, W. H.; Schrank,
B.; Stein, C.; Kostopulos, P.; Lubik, S.; Wekwerth, K.; Dengler, R.; Troeger, M.;
Wuerz, A.; Hoge, A.; Schrader, C.; Schimke, N.; Krampﬂ, K.; Petri, S.; Zierz, S.; Eger,
K.; Neudecker, S.; Traufeller, K.; Sievert, M.; Neundorfer, B.; Hecht, M. High dose
vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole:
results of a placebo-controlled double-blind study. J. Neural Transm. 112:649–660;
2005.
[29] Cashman, N. R.; Durham, H. D.; Blusztajn, J. K.; Oda, K.; Tabira, T.; Shaw, I. T.;
Dahrouge, S.; Antel, J. P. Neuroblastoma × spinal cord (NSC) hybrid cell lines
resemble developing motor neurons. Dev. Dyn. 194:209–221; 1992.
[30] Thor, H.; Smith, M. T.; Hartzell, P.; Bellomo, G.; Jewell, S. A.; Orrenius, S. The
metabolism of menadione (2-methyl-1,4-naphthoquinone) by isolated hepato-
cytes: a study of the implications of oxidative stress in intact cells. J. Biol. Chem.
257:12419–12425; 1982.
[31] Cookson, M. R.; Ince, P. G.; Shaw, P. J. Peroxynitrite and hydrogen peroxide induced
cell death in the NSC34 neuroblastoma × spinal cord cell line: role of poly (ADP-
ribose) polymerase. J. Neurochem. 70:501–508; 1998.
[32] Ertl, P.; Rohde, B.; Selzer, P. Fast calculation of molecular polar surface area as a
sum of fragment-based contributions and its application to the prediction of drug
transport properties. J. Med. Chem. 43:3714–3717; 2000.[33] Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and
computational approaches to estimate solubility and permeability in drug
discovery and development settings. Adv. Drug Delivery Rev. 23:3–25; 1997.
[34] Henderson, C. E.; Bloch-Gallego, E.; Camu, W. Puriﬁed embryonic motoneurons.
In: Cohen, J., Wilkin, G.P. (Eds.), Neural Cell Culture: a Practical Approach. IRL
Press, Oxford, pp. 69–81; 1995.
[35] Ghiselli, A.; Seraﬁni, M.; Maiani, G.; Azzini, E.; Ferro-Luzzi, A. A ﬂuorescence-based
method for measuring total plasma antioxidant capability. Free Radic. Biol. Med.
18:29–36; 1995.
[36] Zhu, M.; Fahl, W. E. Functional characterization of transcription regulators that
interact with the electrophile response element. Biochem. Biophys. Res. Commun.
289:212–219; 2001.
[37] Wood-Allum, C. A.; Barber, S. C.; Kirby, J.; Heath, P.; Holden, H.; Mead, R.;
Higginbottom, A.; Allen, S.; Beaujeux, T.; Alexson, S. E.; Ince, P. G.; Shaw, P. J.
Impairment of mitochondrial anti-oxidant defence in SOD1-related motor neuron
injury and amelioration by ebselen. Brain 129:1693–1709; 2006.
[38] Benjamini, Y.; Hochberg, Y. Controlling the false discovery rate: a practical and
powerful approach to multiple testing. J. R. Stat. Soc. B 57:289–300; 1995.
[39] Borchelt, D. R.; Lee, M. K.; Slunt, H. S.; Guarnieri, M.; Xu, Z. S.; Wong, P. C.; Brown
Jr., R. H.; Price, D. L.; Sisodia, S. S.; Cleveland, D. W. Superoxide dismutase 1 with
mutations linked to familial amyotrophic lateral sclerosis possesses signiﬁcant
activity. Proc. Natl. Acad. Sci. USA 91:8292–8296; 1994.
[40] Liochev, S. I.; Chen, L. L.; Hallewell, R. A.; Fridovich, I. Superoxide-dependent
peroxidase activity of H48Q: a superoxide dismutase variant associated with
familial amyotrophic lateral sclerosis. Arch. Biochem. Biophys. 346:263–268;
1997.
[41] Yim, M. B.; Kang, J. H.; Yim, H. S.; Kwak, H. S.; Chock, P. B.; Stadtman, E. R. A gain-
of-function of an amyotrophic lateral sclerosis-associated Cu,Zn-superoxide
dismutase mutant: an enhancement of free radical formation due to a decrease
in Km for hydrogen peroxide. Proc. Natl. Acad. Sci. USA 93:5709–5714; 1996.
[42] Hough, M. A.; Grossmann, J. G.; Antonyuk, S. V.; Strange, R. W.; Doucette, P. A.;
Rodriguez, J. A.;Whitson, L. J.; Hart, P. J.; Hayward, L. J.; Valentine, J. S.; Hasnain, S. S.
Dimer destabilization in superoxide dismutase may result in disease-causing
properties: structures of motor neuron disease mutants. Proc. Natl. Acad. Sci. USA
101:5976–5981; 2004.
[43] Cookson, M. R.; Menzies, F. M.; Manning, P.; Eggett, C. J.; Figlewicz, D. A.; McNeil,
C. J.; Shaw, P. J. Cu/Zn superoxide dismutase (SOD1) mutations associated with
familial amyotrophic lateral sclerosis (ALS) affect cellular free radical release in
the presence of oxidative stress. Amyotroph. Lateral Scler. Other Motor Neuron
Disord. 3:75–85; 2002.
[44] Kelder, J.; Grootenhuis, P. D.; Bayada, D. M.; Delbressine, L. P.; Ploemen, J. P. Polar
molecular surface as a dominating determinant for oral absorption and brain
penetration of drugs. Pharm. Res. 16:1514–1519; 1999.
[45] Baur, J. A.; Sinclair, D. A. Therapeutic potential of resveratrol: the in vivo evidence.
Nat. Rev. Drug Discovery 5:493–506; 2006.
[46] Kaneko, T.; Tahara, S.; Takabayashi, F. Suppression of lipid hydroperoxide-induced
oxidative damage to cellular DNA by esculetin. Biol. Pharm. Bull. 26:840–844;
2003.
[47] Lin,W. L.; Wang, C. J.; Tsai, Y. Y.; Liu, C. L.; Hwang, J. M.; Tseng, T. H. Inhibitory effect
of esculetin on oxidative damage induced by t-butyl hydroperoxide in rat liver.
Arch. Toxicol. 74:467–472; 2000.
[48] Sud'ina, G. F.; Mirzoeva, O. K.; Pushkareva, M. A.; Korshunova, G. A.; Sumbatyan,
N. V.; Varfolomeev, S. D. Caffeic acid phenethyl ester as a lipoxygenase inhibitor
with antioxidant properties. FEBS Lett. 329:21–24; 1993.
[49] Natarajan, K.; Singh, S.; Burke Jr., T. R.; Grunberger, D.; Aggarwal, B. B. Caffeic acid
phenethyl ester is a potent and speciﬁc inhibitor of activation of nuclear
transcription factor NF-kappa B. Proc. Natl. Acad. Sci. USA 93:9090–9095; 1996.
[50] Ozyurt, B.; Ozyurt, H.; Akpolat, N.; Erdogan, H.; Sarsilmaz, M. Oxidative stress in
prefrontal cortex of rat exposed to MK-801 and protective effects of CAPE. Prog.
Neuropsychopharmacol. Biol. Psychiatry 31:832–838; 2007.
[51] Estevez, A. G.; Spear, N.; Manuel, S. M.; Radi, R.; Henderson, C. E.; Barbeito, L.;
Beckman, J. S. Nitric oxide and superoxide contribute to motor neuron apoptosis
induced by trophic factor deprivation. J. Neurosci. 18:923–931; 1998.
[52] Kirby, J.; Halligan, E.; Baptista, M. J.; Allen, S.; Heath, P. R.; Holden, H.; Barber, S. C.;
Loynes, C. A.; Wood-Allum, C. A.; Lunec, J.; Shaw, P. J. Mutant SOD1 alters the
motor neuronal transcriptome: implications for familial ALS. Brain 128:
1686–1706; 2005.
[53] West, M.; Mhatre, M.; Ceballos, A.; Floyd, R. A.; Grammas, P.; Gabbita, S. P.;
Hamdheydari, L.; Mai, T.; Mou, S.; Pye, Q. N.; Stewart, C.;West, S.;Williamson, K. S.;
Zemlan, F.; Hensley, K. The arachidonic acid 5-lipoxygenase inhibitor nordihy-
droguaiaretic acid inhibits tumor necrosis factor alpha activation of microglia and
extends survival of G93A-SOD1 transgenic mice. J. Neurochem. 91:133–143; 2004.
[54] Hensley, K.; Abdel-Moaty, H.; Hunter, J.; Mhatre, M.; Mou, S.; Nguyen, K.;
Potapova, T.; Pye, Q. N.; Qi, M.; Rice, H.; Stewart, C.; Stroukoff, K.; West, M.
Primary glia expressing the G93A-SOD1 mutation present a neuroinﬂamma-
tory phenotype and provide a cellular system for studies of glial inﬂammation.
J. Neuroinﬂammation 3:2; 2006.
[55] Lee, M.; You, H. J.; Cho, S. H.; Woo, C. H.; Yoo, M. H.; Joe, E. H.; Kim, J. H. Implication
of the small GTPase Rac1 in the generation of reactive oxygen species in response
to beta-amyloid in C6 astroglioma cells. Biochem. J. 366:937–943; 2002.
[56] Mirzoeva, O. K.; Calder, P. C. The effect of propolis and its components on
eicosanoid production during the inﬂammatory response. Prostaglandins Leuko-
trienes Essent. Fatty Acids 55:441–449; 1996.
[57] Williamson, J. M.; Meister, A. Stimulation of hepatic glutathione formation by
administration of L-2-oxothiazolidine-4-carboxylate, a 5-oxo-L-prolinase sub-
strate. Proc. Natl. Acad. Sci. USA 78:936–939; 1981.
1138 S.C. Barber et al. / Free Radical Biology & Medicine 46 (2009) 1127–1138[58] Volterra, A.; Trotti, D.; Tromba, C.; Floridi, S.; Racagni, G. Glutamate uptake
inhibition by oxygen free radicals in rat cortical astrocytes. J. Neurosci.
14:2924–2932; 1994.
[59] Khaldy, H.; Escames, G.; Leon, J.; Vives, F.; Luna, J. D.; Acuna-Castroviejo, D.
Comparative effects of melatonin, L-deprenyl, Trolox and ascorbate in the
suppression of hydroxyl radical formation during dopamine autoxidation in
vitro. J. Pineal Res. 29:100–107; 2000.
[60] Possel, H.; Noack, H.; Keilhoff, G.; Wolf, G. Life imaging of peroxynitrite in rat
microglial and astroglial cells: role of superoxide and antioxidants. Glia
38:339–350; 2002.
[61] Ferri, A.; Gabbianelli, R.; Casciati, A.; Celsi, F.; Rotilio, G.; Carri, M. T. Oxidative
inactivation of calcineurin by Cu,Zn superoxide dismutase G93A, a mutant typical
of familial amyotrophic lateral sclerosis. J. Neurochem. 79:531–538; 2001.
[62] Mills, E. M.; Gunasekar, P. G.; Pavlakovic, G.; Isom, G. E. Cyanide-induced apoptosis
and oxidative stress in differentiated PC12 cells. J. Neurochem. 67:1039–1046;
1996.
[63] Chang, W. S.; Lin, C. C.; Chuang, S. C.; Chiang, H. C. Superoxide anion scavenging
effect of coumarins. Am. J. Chin. Med. 24:11–17; 1996.
[64] Minsavage, G. D.; Dillman III, J. F. Bifunctional alkylating agent-induced p53 and
nonclassical nuclear factor {kappa}B responses and cell death are altered by
caffeic acid phenethyl ester: a potential role for antioxidant/electrophilic
response-element signaling. J. Pharmacol. Exp. Ther. 321:202–212; 2007.
[65] Baur, J. A.; Pearson, K. J.; Price, N. L.; Jamieson, H. A.; Lerin, C.; Kalra, A.; Prabhu,
V. V.; Allard, J. S.; Lopez-Lluch, G.; Lewis, K.; Pistell, P. J.; Poosala, S.; Becker, K. G.;
Boss, O.; Gwinn, D.; Wang, M.; Ramaswamy, S.; Fishbein, K. W.; Spencer, R. G.;
Lakatta, E. G.; Le Couteur, D.; Shaw, R. J.; Navas, P.; Puigserver, P.; Ingram, D. K.;
de Cabo, R.; Sinclair, D. A. Resveratrol improves health and survival of mice on a
high-calorie diet. Nature 444:337–342; 2006.
[66] Bigby, T. D. The yin and the yang of 5-lipoxygenase pathway activation. Mol.
Pharmacol. 62:200–202; 2002.
[67] Ginn-Pease, M. E.; Whisler, R. L. Redox signals and NF-kappaB activation in T cells.
Free Radic. Biol. Med. 25:346–361; 1998.
[68] Kensler, T. W.; Wakabayashi, N.; Biswal, S. Cell survival responses to environ-
mental stresses via the Keap1–Nrf2–ARE pathway. Annu. Rev. Pharmacol. Toxicol.
47:89–116; 2007.
[69] Thimmulappa, R. K.; Mai, K. H.; Srisuma, S.; Kensler, T. W.; Yamamoto, M.; Biswal,
S. Identiﬁcation of Nrf2-regulated genes induced by the chemopreventive agent
sulforaphane by oligonucleotide microarray. Cancer Res. 62:5196–5203; 2002.
[70] Lee, J. M.; Calkins, M. J.; Chan, K.; Kan, Y. W.; Johnson, J. A. Identiﬁcation of the
NF-E2-related factor-2-dependent genes conferring protection against oxidativestress in primary cortical astrocytes using oligonucleotide microarray analysis.
J. Biol. Chem. 278:12029–12038; 2003.
[71] Ilhan, A.; Koltuksuz, U.; Ozen, S.; Uz, E.; Ciralik, H.; Akyol, O. The effects of caffeic
acid phenethyl ester (CAPE) on spinal cord ischemia/reperfusion injury in rabbits.
Eur. J. Cardiothorac. Surg. 16:458–463; 1999.
[72] Ilhan, A.; Akyol, O.; Gurel, A.; Armutcu, F.; Iraz, M.; Oztas, E. Protective effects of
caffeic acid phenethyl ester against experimental allergic encephalomyelitis-
induced oxidative stress in rats. Free Radic. Biol. Med. 37:386–394; 2004.
[73] Khan, M.; Elango, C.; Ansari, M. A.; Singh, I.; Singh, A. K. Caffeic acid phenethyl
ester reduces neurovascular inﬂammation and protects rat brain following
transient focal cerebral ischemia. J. Neurochem. 102:365–377; 2007.
[74] Tsai, T. H.; Huang, C. T.; Shum, A. Y.; Chen, C. F. Simultaneous blood and biliary
sampling of esculetin by microdialysis in the rat. Life Sci. 65:1647–1655; 1999.
[75] Celli, N.; Mariani, B.; Dragani, L. K.; Murzilli, S.; Rossi, C.; Rotilio, D.
Development and validation of a liquid chromatographic-tandem mass spectro-
metric method for the determination of caffeic acid phenethyl ester in rat
plasma and urine. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 810:129–136;
2004.
[76] Celli, N.; Dragani, L. K.; Murzilli, S.; Pagliani, T.; Poggi, A. In vitro and in vivo
stability of caffeic acid phenethyl ester, a bioactive compound of propolis. J. Agric.
Food Chem. 55:3398–3407; 2007.
[77] Marsicano, G.; Moosmann, B.; Hermann, H.; Lutz, B.; Behl, C. Neuroprotective
properties of cannabinoids against oxidative stress: role of the cannabinoid
receptor CB1. J. Neurochem. 80:448–456; 2002.
[78] Gassen, M.; Pergande, G.; Youdim, M. B. Antioxidant properties of the
triaminopyridine, ﬂupirtine. Biochem. Pharmacol. 56:1323–1329; 1998.
[79] Suh, J. H.; Shenvi, S. V.; Dixon, B. M.; Liu, H.; Jaiswal, A. K.; Liu, R. M.; Hagen, T. M.
Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione
synthesis, which is reversible with lipoic acid. Proc. Natl. Acad. Sci. USA
101:3381–3386; 2004.
[80] Andreassen, O. A.; Dedeoglu, A.; Friedlich, A.; Ferrante, K. L.; Hughes, D.; Szabo, C.;
Beal, M. F. Effects of an inhibitor of poly(ADP-ribose) polymerase, desmethylse-
legiline, trientine, and lipoic acid in transgenic ALS mice. Exp. Neurol. 168:
419–424; 2001.
[81] Perez, M. J.; Cederbaum, A. I. Spin trapping agents (Tempol and POBN) protect
HepG2 cells overexpressing CYP2E1 against arachidonic acid toxicity. Free Radic.
Biol. Med. 30:734–746; 2001.
[82] Park, K. S.; Kim, H. J.; Choi, W. J.; Kim, M.; Lee, K. W. Detection method of the
adjacent motor neuronal death in an in vitro co-culture model of familial ALS-
associated Cu/Zn superoxide dismutase. Biotechnol. Lett. 26:1201–1205; 2004.
